Get the Stockscreener App
27.14
1.88%
-0.52
After Hours:
27.35
0.21
+0.77%
Ultragenyx Pharmaceutical Inc stock is traded at $27.14, with a volume of 2.32M.
It is down -1.88% in the last 24 hours and down -25.68% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$27.66
Open:
$28.22
24h Volume:
2.32M
Relative Volume:
1.40
Market Cap:
$2.57B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-4.1947
EPS:
-6.47
Net Cash Flow:
$-439.53M
1W Performance:
-3.11%
1M Performance:
-25.68%
6M Performance:
-37.47%
1Y Performance:
-39.30%
1-Day Range:
$27.01
$28.46
1-Week Range:
$27.00
$28.48
52-Week Range:
$25.81
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
27.14 | 2.62B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.16 | 120.29B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.58 | 60.26B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.80 | 43.10B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.89 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.94 | 33.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Ultragenyx's Strategic Momentum: Catalyzing Long-Term Value Through Revenue Growth and Gene Therapy Innovation - AInvest
Ultragenyx Pharmaceutical Inc. to Host Conference Call for Q2 2025 Financial Results and Corporate Update - Quiver Quantitative
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update - GlobeNewswire
Rare Disease Leader Ultragenyx Sets Q2 2025 Earnings Call: Key Updates Expected for Genetic Disease Pipeline - Stock Titan
Ultragenyx Pharmaceutical Inc. stock momentum explainedWeekly Portfolio Update with ROI Focus - Newser
Ultragenyx Pharmaceutical Inc. stock trendline breakdownLow Risk Stock Selection Strategy Guide - Newser
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionBreakout Watcher with Entry and Exit Alerts - Newser
Ultragenyx Pharmaceutical Inc. Shows Early Signs of Technical StrengthTriple Digit Growth Focused Trade Plan Reviewed - beatles.ru
Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst (NASDAQ:RARE) - Seeking Alpha
Custom strategy builders for tracking Ultragenyx Pharmaceutical Inc.Free Daily Momentum Screener With Alerts - Newser
Ultragenyx Pharmaceutical (NASDAQ:RARE) Now Covered by Analysts at HC Wainwright - Defense World
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks - Benzinga
Does Ultragenyx Pharmaceutical Inc. stock perform well during market downturnsExpert guidance for superior capital growth - jammulinksnews.com
Ultragenyx Pharma stock rating initiated at Buy by H.C. Wainwright - Investing.com
What is the dividend policy of Ultragenyx Pharmaceutical Inc. stockCapitalize on proven investment strategies - jammulinksnews.com
What institutional investors are buying Ultragenyx Pharmaceutical Inc. stockCapitalize on proven investment strategies - jammulinksnews.com
How hedge fund analytics apply to Ultragenyx Pharmaceutical Inc. stockReal-Time AI Generated Market Forecast - Newser
Visual trend scoring systems applied to Ultragenyx Pharmaceutical Inc.Free Growth Focused Entry Plan Suggestions - Newser
Ultragenyx Pharmaceutical Inc. stock trendline breakdown Capital Protection Strategy With Risk Analysis - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
What catalysts could drive Ultragenyx Pharmaceutical Inc. stock higher in 2025Free Daily Trading Room Entry - jammulinksnews.com
How does Ultragenyx Pharmaceutical Inc. compare to its industry peersMaximize your portfolio’s earning potential - jammulinksnews.com
How strong is Ultragenyx Pharmaceutical Inc. company’s balance sheetGet real-time alerts on high-potential stocks - jammulinksnews.com
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityElite Stock Shortlist - Newser
New Product Launches: Will They Boost Ultragenyx Pharmaceutical Inc. Stock in 2025Top Rated Trade Entries - Newser
How Resilient Is Ultragenyx Pharmaceutical Inc. Stock During Economic DownturnsCarefully Curated High Return Stocks - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Will Ultragenyx Pharmaceutical Inc. stock split in the near futureTurbocharged investment results - jammulinksnews.com
What analysts say about Ultragenyx Pharmaceutical Inc. stockFree Trend-Following Techniques - Autocar Professional
Ultragenyx Pharmaceutical Inc. Stock Analysis and ForecastFree Stock Market Return Analysis - Autocar Professional
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intuitive Surgical (ISRG), Quest Diagnostics (DGX) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Clinical, - openPR.com
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What drives Ultragenyx Pharmaceutical Inc. stock priceRapid portfolio appreciation - Autocar Professional
RARE ALERT: Levi & Korsinsky Investigates Ultragenyx Pharmaceutical Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
RARE ACTIVE INVESTIGATION: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Ultragenyx Pharmaceutical (RARE) Gets a Complete Response Letter for UX111 - Insider Monkey
Is Ultragenyx Pharmaceutical Inc. a good long term investmentConsistently high returns - jammulinksnews.com
Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ultragenyx Pharmaceutical Inc. (RARE) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Investors in Ultragenyx Pharmaceutical Inc. (RARE) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Lost Money on Ultragenyx Pharmaceutical Inc. (RARE)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):